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Abstract 
Aims 
The mode of action by which doxapram acts as a respiratory stimulant in humans is 
controversial. Studies in rodent models, have shown that doxapram is a more potent and 
selective inhibitor of TASK-1 and TASK-1/TASK-3 heterodimer channels, than TASK-3. Here 
we investigate the direct effect of doxapram and chirally separated, individual positive and 
negative enantiomers of the compound, on both human and mouse, homodimeric and 
heterodimeric variants of TASK-1 and TASK-3.  
 
Methods 
Whole-cell patch-clamp electrophysiology on tSA201 cells was used to assess the potency of 
doxapram on cloned human or mouse TASK-1, TASK-3 and TASK-2 channels. Mutations of 




Doxapram was an equipotent inhibitor of human TASK-1 and TASK-3 channels, compared 
with mouse channel variants, where it was more selective for TASK-1 and heterodimers of 
TASK-1 and TASK-3. The effect of doxapram could be attenuated by either the removal of 
the C-terminus of human TASK-3 channels or mutations of particular hydrophobic residues 
in the pore-lining region. These mutations, however, did not alter the effect of a known 
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more potent antagonist of TASK channels, than doxapram, whereas the negative 
enantiomer, GAL-053, had little inhibitory effect. 
 
Conclusion 
These data show that in contrast to rodent channels, doxapram is a potent inhibitor of both 
TASK-1 and TASK-3 human channels, providing further understanding of the 
pharmacological profile of doxapram in humans and informing the development of new 
therapeutic agents.   
 
Key Words: 




Doxapram (1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone) is a central 
respiratory stimulant used clinically in the treatment of post-operative respiratory 
depression, acute respiratory failure, chronic obstructive pulmonary disorder and apnoea in 
premature infants. 1,2 Doxapram’s analeptic respiratory action is characterised by an 
increase in tidal volume and a slight increase in respiratory rate, when administered 
intravenously.3  The compound’s mode of action has long been debated, with conflicting 
data from animal and human models.2 Recent studies propose a mode of action that occurs 
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bodies and a subsequent release of catecholamines and other neurotransmitters.4,5 This 
results in the prevention or reversal of central nervous system depressant or narcotic–
induced respiratory failure. Neurotransmitter release by type 1 cells occurs in response to 
an increase in cytosolic calcium (Ca2+) levels, mediated by voltage-gated calcium channels in 
response to an electrical signal causing the membrane to depolarise.  
 
A number of potassium (K) channels have been identified in type 1 cells, including delayed 
rectifier K+-channels, calcium-activated K-channels, HERG channels and TWIK-related acid-
sensitive K+-channels (TASK).6-10 The resting membrane K conductance of carotid bodies, has 
been shown to be predominantly mediated by a TASK-like current, which when inhibited, 
results in an influx of Ca2+ ions and subsequent membrane depolarisation.11 Both TASK-1 
(KCNK3) and TASK-3 (KCNK9) are expressed in the carotid body,12,13 present as a mixture of 
homodimeric and heterodimeric TASK-1 and TASK-3 channels, with heterodimeric channels, 
the predominant form.13,14 Stimulation of chemoreceptors by doxapram is thought to occur 
via the direct inhibition of a TASK channel.15,16 Indeed, mice lacking either TASK-1 or both 
TASK-1 and TASK-3 have impaired carotid body function.17,18   
 
Previous work,15 on cloned rat TASK channels, showed that doxapram’s selectivity favoured 
TASK-1 homodimeric channels, followed by TASK-1/TASK-3 heterodimeric channels and to a 
lesser extent TASK-3 homodimeric channels, with EC50’s of 410 nM, 9 µM and 37 µM 
respectively. With a therapeutic range of 4 – 5 µM for doxapram in the blood plasma,19 
respiratory stimulation in the rat would appear to occur predominantly through 
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thought to reside at the carboxy intracellular domains of the channels, where homology 
between TASK-1 and TASK-3 sequence is the least.15 
 
Later studies from a number of groups identified, using molecular modelling, a common 
intracellular binding site at the pore region of rat TASK channels that was thought to 
transduce the inhibitory effects of a number of related compounds, A1899, PKTHPP and 
doxapram.20-22 Four amino acids in the pore region of rat TASK-3, Leucine (L) 122, Glycine 
(G) 236, L 239, and valine (V) 242, were shown to effect the efficacy of compounds such as 
doxapram, when mutated to an aspartate (D), highlighting the importance of this region in 
TASK channels for the action of these compound types.22 Interestingly, one of these 
highlighted amino acids, G 236 when mutated to an arginine (R) is responsible for the 
condition, Birk Barel mental retardation syndrome.23 
 
Doxapram is a racemic compound which is comprised of positive (+) and negative (-) 
enantiomers. Galleon Pharmaceuticals showed that by chirally separating doxapram into its 
positive (+) (GAL-054) and negative (-) (GAL-053) enantiomers, that ventilatory stimulation 
was conferred by GAL-054 and not GAL-053. Moreover, the adverse events such as 
dysrhythmias, agitation and seizures, observed with doxapram, were only observed with 
GAL-053.24-27 Phase 1 trials with GAL-054 in healthy volunteers, however, found that GAL-
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In this present study, using electrophysiological techniques and heterologous cell expression 
systems we investigated the direct effect of doxapram on human and mouse cloned 
homodimeric and heterodimeric TASK channels and a structurally related channel, from the 
TALK subfamily, TASK-2.  
 
Secondly, we further investigated the mode of action of doxapram on human TASK-3 
channels, using pore specific mutations and C-terminally truncated channels. 
 
Finally, we studied the effect of positive and negative enantiomers of doxapram, GAL-054 
and GAL-053, in isolation on human homodimeric TASK-1 and TASK-3 channels. A 
preliminary account of some of these data has been reported previously.28 
 
Results 
Doxapram is a potent inhibitor of both TASK-1 and TASK-3 human cloned channels 
Our initial experiments sought to determine the pharmacological profile of doxapram on 
homodimeric TASK-1 and TASK-3 channels and a structurally related channel from the TALK 
subfamily, TASK-2, using cloned human channels, transiently expressed in tSA201 cells and 
studied using whole-cell patch clamp electrophysiology. Surprisingly, unlike for cloned rat 
TASK channels,15,22 doxapram showed an increase potency against human TASK-3 channels, 
over a range of concentrations (0.3 – 100 µM), with a calculated 50% effective 
concentration (EC50) of 2.5 µM [95% CI: 1.9 to 3.5] and a Hill slope of 0.8 [95% CI: 0.5 to 1.1]. 











This article is protected by copyright. All rights reserved. 
channels, with an observed EC50 of 4.0 µM [95% CI: 2.1 to 7.9] and a Hill slope of 0.8 [95% CI: 
0.7 to 1.0] for TASK-1 (Figures 1A and 1C). Similar to effects seen with rodent channels,15 
recovery from inhibition of TASK-1 by doxapram (10 µM) was slow and mostly incomplete, 
whilst for TASK-3, recovery from doxapram (10 µM) inhibition was faster and more 
complete. By contrast, doxapram (10 µM) had little effect on currents through TASK-2 
channels (Figure 1E, 1F). Acute application of 10 µM doxapram to WT TASK-2 resulted in an 
inhibition of 7% [95% CI: -3 to 16; n = 6], which was significantly less (p < 0.05, one-way 
Anova, followed by a Dunnett’s multiple comparisons test, [95% CI of difference:  35 to 61]) 
than the 55% inhibition [95% CI: 45 to 65; n = 8] seen for TASK-1 channels and also 
significantly less [p < 0.05, 95% CI of difference:  48 to 75] than the 68% [95% CI: 62 to 74; n 
= 8] inhibition seen for TASK-3 channels (Figure 1E). 
 
Doxapram is a more potent inhibitor of mouse TASK-1 than of mouse TASK-3 channels and 
mouse TASK-3/-1 heterodimer channels. 
As the effect of doxapram was different to that demonstrated on cloned rat channels,15 we 
looked to determine whether the difference observed with human cloned channels was a 
species-dependent effect. To do this, we studied the effect of doxapram on cloned mouse 
channels over a range of concentrations. Similar to cloned rat TASK-1 and TASK-3 channels, 
TASK-1 and TASK-3 channels from mouse (mur) were inhibited differentially by doxapram. 
Acute application of doxapram to murTASK-1 channels at a concentration of 1, 3 and 10 µM 
resulted in current inhibition of 28% [95% CI: 14 to 41, n=4], 43% [95% CI: 38 to 49, n=3] and 
58% [95% CI: 50 to 66, n=8], respectively, with a calculated 50% effective concentration of 
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concentrations of 10 and 100 µM resulted in current inhibition of 21% [95% CI: 13 to 29, 
n=6] and 56% [95% CI: 42 to 69, n=6], respectively, with an estimated 50% effective 
concentration > 100 µM, around 100 fold higher than seen for murTASK-1 channels (Figure 
2B). The inhibitory effect of doxapram was significantly smaller at 10 µM for murTASK-3 [p < 
0.05, 95% CI of difference: 27 to 48], compared to murTASK-1, as was observed with rat 
TASK channels.15  
 
As the predominant channel formed in rat carotid bodies are heterodimers of TASK-1 and 
TASK-3,13,14 we also tested the effect of doxapram on forced heterodimers of murTASK-1 
and 3 channels. Combining murTASK-1 channels with murTASK-3 channels, conferred 
sensitivity to doxapram. Doxapram (10 µM) inhibited murTASK-3/murTASK-1 heterodimer 
channels by 42% [95% CI = 29 to 56; n = 5], which was an intermediary effect between 
homodimeric murTASK-1 (58% [95% CI:  50 to 66; n = 8]) and homodimeric murTASK-3 (21% 
[95% CI: 13 to 29; n = 6] Fig 2C). Interestingly doxapram (10 µM) inhibited the reverse 
murTASK-1/murTASK-3 heterodimer channels by 58% [95% CI: 45 to 70; n = 5, Figure 2C, D], 
which was similar to effects seen on homodimeric murTASK-1 channels (p > 0.05 [95% CI of 
difference: -14 to 16]). 
 
The Carboxy terminal domains are involved in transducing the effect of doxapram 
The difference in sensitivity to doxapram seen between rodent TASK-1 and TASK-3 channels 
was suggested to occur, although not exclusively, due to structural differences between the 
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identity, with the least identity occurring in their intracellular carboxy terminal domains. 
MurTASK-3 channels have many of their regulatory sites, including phosphorylation sites 
located in their C-terminal domains (Figure 3A). Removal of the C-terminus from murTASK-3 
by the incorporation of a stop codon at position 250 (Δ250), resulted in a functional channel, 
but with a significantly (P < 0.05, [95% CI of difference: -141 to -91], unpaired t-test) reduced 
current of 18 pA pF-1 [95% CI: -1 to 36, n=5], compared to an average WT current of 134 pA 
pF-1 [95% CI: 110 to 158, n=5], when transfecting 125 ng µL-1 of DNA. Inhibition of this 
reduced current by doxapram (10 µM) was also severely attenuated (p<0.05 [95% CI of 
difference: -27 to -8]) compared to WT (Figure 3B, 3C). Doxapram (10 µM) inhibited murT3_ 
Δ250 by 4% [95% CI: -3 to 10, n = 5, Figure 3B]. 
 
The Carboxy terminal domains of human TASK-1 and TASK-3 are also structurally 
different, but the effect of doxapram is equal 
This difference in effect by doxapram on rodent channels, if explained by their structurally 
different carboxy terminals, cannot, however be easily translated to human channels as the 
effect of doxapram on both channels is similar. Like rodent channels, human TASK-1 and 
TASK-3 channels share 58% identity, with the majority of the structural dissimilarity 
occurring at the carboxy terminals of the channels. As seen for murTASK-3, truncating the 
channel to remove the C-terminal of the human TASK-3 channel (T3_Δ250, see Figure 4A) 
significantly attenuated the effect of doxapram (p < 0.05 [95% CI of difference: -57 to -41], 
n=8), with inhibition by 10 µM doxapram reduced to 19% [95% CI: 12 to 26] (Figure 4B, C). 
For human TASK-3, truncating the C-terminus of TASK-3, significantly (p < 0.05, [95% CI of 
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n=8], compared to an average WT current of 56 pA pF-1 [95% CI:  46 to 65, n=16], when 
transfecting 500 ng  µL-1 of DNA. Interestingly, current recorded through human TASK-3 
channels in these experimental conditions is almost 8-fold smaller than is observed for Mur 
TASK-3 channels. 
 
Mutation of identified amino acids in the pore region of human TASK channels increased 
channel currents and reduced the efficacy of doxapram 
Evidence from molecular modelling, docking and aspartate scanning mutagenesis of rat 
TASK-1 and TASK-3, using inhibitory compounds such as A1899, PKTHPP and doxapram have 
suggested a common intracellular binding site, comprised of hydrophobic residues from the 
M2 and M4 transmembrane domains, within the intracellular pore region of these 
channels.20-22,29 The key amino acids (AA) identified are Leucine (L) 122, Glycine (G) 236, 
L239 and Valine (V) 242, which are homologous in the human clones (Figure 5A, 5B). In rat 
TASK-3 mutation of these specific AA to aspartate (D), considerably affected the efficacy of 
these compounds highlighting the importance of this region for the action of these 
particular compound types.22  
 
We introduced each of the identified AA into human TASK-3 and characterised currents 
mediated through each homodimeric mutated channel (L122D, G236D, L239D and V242D). 
Mutation of either a hydrophobic leucine (L) or a small uncharged glycine (G) residue to a 
charged aspartate residue (D), resulted in functional channels with significantly (P < 0.05, 
one-way ANOVA followed by a Dunnett’s multiple comparisons test) increased currents 
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between current seen at -40 mV and -80 mV was: 56 pA pF-1 [95% CI: 46 to 66, n = 15] for 
WT; 92 pA pF-1 [95% CI: 81 to 102, n = 12] for L122D; 131 pA pF-1 [95% CI: 103 to 159, n = 7] 
for G236D; 96 pA pF-1 [95% CI: 82 to 111, n = 5] for L239D; and 118 pA pF-1 [95% CI: 72 to 
164, n = 6] for V242D, compared with an average whole-cell current of 2 pA pF-1 [95% CI: 1.5 
to 2.3, n = 5] for GFP-only transfected cells. All mutated currents were outwardly-rectifying, 
with a mean zero current potential of -85 mV [95% CI: -88 to -81, n = 12] for L122D;  -83 mV 
[95% CI = -86 to -80, n = 7] for G236D; -82 mV [95% CI: -87 to -77, n = 5] for L239D) and -83 
mV [95% CI: -89 to -77, n = 6] for V242D, compared with -31 mV [95% CI: -43 to -20, n = 5] 
for GFP-only cells. None of the zero current potentials for the mutant channels were 
significantly different (P > 0.05) from WT which was -82 mV [95% CI: = -85 to -79, n = 15] 
(Figure 6B). We then tested whether these mutations modified the potency of doxapram, as 
had been observed in rat channels.22 All four mutations significantly reduced (P < 0.05) 
doxapram potency, with the largest reduction in effect observed with the L122D mutation 
(Figure 6C, 6D). The percentage inhibition was 6 % [95% CI: 3 to 9, n = 10] for L122D; 26 % 
[95% CI: 15 to 36, n = 8] for G236D; 13 % [95% CI: 6 to 20, n = 8] for L239D; and 27 % [95% 
CI: 13 to 41, n = 5] for V242D compared to 62 % [95% CI: 57 to 67, n = 16] for WT. To further 
confirm the consensus that doxapram acts within the intracellular pore of TASK channels,15 
we studied the effect of another well-known TASK-3 inhibitor, zinc, which is proposed to 
have its mode of action from the extracellular side of the channel.30,31 Using the aspartate 
mutant channel, L122D, we found that the effect of zinc, was not affected (p > 0.05 [95% CI 
of difference: -17 to 3]) by this pore mutation, with 100 µM zinc giving an inhibition of 87% 
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Enantomeric separation of doxapram reveals a stereoselective effect on TASK channels 
Doxapram is a racemic compound that can be chirally separated into a (+) – enantiomer 
(GAL-054) and (-) – enantiomer (GAL-053) (Galleon Pharmaceuticals Inc.).27 The eutomer 
(GAL-054) was found to be a superior respiratory stimulant compared to doxapram when 
tested in animal models, whilst the distomer (GAL-053) was markedly inferior.24-26 We 
looked to see what effect these separate enantiomers of doxapram had on human TASK-1 
and TASK-3 current. Compared with doxapram and GAL-053, GAL-054 was twice as potent 
as doxapram with EC50s of ~1.6 and 1.4 µM for human TASK-1 and TASK-3 respectively. GAL-
053 had reduced potency on TASK-1 and TASK-3, with EC50s ~336 and 286 µM, respectively. 
Acute application of 1, 3 and 10 µM GAL-054 to human TASK-1 expressing tsA201 cells, 
resulted in an inhibition of 45% [95% CI: 37 to 53, n = 6]; 54% [95% CI: 52 to 57, n = 5]; and 
75% [95% CI: 71 to 79, n = 6] respectively. For human TASK-3 inhibitions of 43% [95% CI: 30 
to 56, n = 6]; 66% [95% CI: 61 to 72, n = 5]; and 79% [95% CI: 73 to 84, n = 8] were seen for 
the same concentrations (Figure 7A, 7B, 7C, 7D). Acute application of 10, 100 and 300 µM 
GAL-053 to human TASK-1, resulted in an inhibition of 3% [95% CI: -9 to 15, n = 6]; 24% [95% 
CI: 13 to 35, n = 5] and 47% [95% CI: 38 to 56, n = 5]. For human TASK-3 inhibitions of 8% 
[95% CI:  5 to 12, n = 6]; 35% [95% CI: 31 to 38, n = 6] and 50% [95% CI: 43 to 56, n = 5] were 
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Discussion 
Doxapram is one of the few respiratory stimulants still in clinical use and has been shown to 
inhibit cloned rat TASK channels and native TASK channels (TASK-1/3 heterodimers) in rat 
type-1 cells 5,15,16,22 with highest potency observed for rat TASK-1 (TASK-1 > TASK-1/3 
heterodimer > TASK-3).  
 
The mode of action by which doxapram acts as a respiratory stimulant in humans is 
controversial. In part, this is a consequence of differing effects observed in various animal 
models. In particular, the stated molecular mechanism by which doxapram has its effect, 
has been characterised entirely in rodents.5 In this study, we characterised the effect of 
doxapram on cloned human TASK channels (TASK-1 and TASK-3), to give a better 
understanding of the pharmacological profile of this drug in humans, and any potential 
clinical consequences for patients.  
 
Interestingly we have found that doxapram is an equally potent inhibitor of both human 
TASK-1 and TASK-3 channels, which is different to that seen previously in rat channels, 
where the drug is 90-fold more potent on TASK-1 or heteromultimers of TASK-1 and TASK-3 
than on TASK-3.15,22 We investigated whether this was a species dependent effect by 
repeating the same experiments on cloned mouse TASK channels and found, as for rat 
channels, that doxapram was a more potent inhibitor of mouse TASK-1 channels and 
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The increased potency of doxapram for TASK-3 channels may not alter the determined 
molecular mechanism by which doxapram has its effect on TASK channels in the carotid 
bodies, as heteromultimers of TASK-1 and TASK-3 are the predominant channel in these 
type 1 cells, at least for rodents.13,14 Its inhibitory effect on human TASK-3 channels may 
however, contribute to the side-effect profile of this compound, in humans. For example, 
changes in systolic blood pressure have been linked to changes in TASK-3 channel 
expression.32 Indeed, some of the major limitations to doxapram’s clinical use has been its 
analeptic and pressor effects, which includes an increase in arousal, panicogenic activity, 
increased hyperventilation, increased blood pressure and heart rate, and convulsions, in 
patients.27,33 Many of these side-effects are observed primarily in patients that already 
suffer from these conditions and typically are manifest during continuous intravenous 
infusion, due the compounds short half-life.34  
 
We also show that the effect of doxapram is restricted to the TASK family of channels, with 
the compound having no effect on a closely related channel member, TASK-2. However, 
inhibitory effects have been observed with TASK-2 at much higher concentrations of 
doxapram (300 µM and 1 mM).15  
 
Removing the C-terminus of TASK-3 channels, both for murine and human TASK-3 channels, 
significantly reduces the effectiveness of doxapram (Figure 3B & 4B). This correlates with 
earlier experiments in rat cloned channels, where C-terminal domain swopping of TASK-1 to 
TASK-3, increased or decreased the sensitivity of the channels to doxapram15 and reduced 
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experiments, was due to the high sequence dissimilarity between rodent TASK-1 and TASK-3 
C-termini. However, for human channels, the potency of doxapram is equal, despite the 
same high sequence dissimilarity in the C-termini between the two channels (Figure 4A), 
making the importance of the C-termini harder to interpret. Due to the importance of this 
region for signalling inputs, such as phosphorylation,36 one can hypothesise that the 
phosphorylation state of the channel may be important for doxapram’s effect, particularly 
as the number of putative phosphorylation sites are different between TASK-1 and TASK-3, 
with more predicted sites on mouse and human TASK-3.37 For human TASK-3 channels, C-
terminal truncation resulted in a 2-fold increase in current. By truncating the channel, it is 
possible that the channel has been pushed into an open state, perhaps by locking the 
channel into a particular phosphorylation state, or because gating at the selectivity filter is 
disrupted by C terminus truncation. Indeed, for known gain-of-function mutations on these 
channels and other related K2P channels, regulation by blockers or activators is modified 
when the link between the C terminus and the selectivity filter is disrupted.37,38 Surprisingly, 
however, truncation of murTASK-3 channels, resulted in a significant reduction in current 
recorded through these channels, but this still attenuated the effect of doxapram. With the 
structure of the intracellular C-termini of K2P channels not determined by existing crystal 
structures, the involvement of this region remains difficult to evaluate. The C-terminal 
domain of another potassium channel, GIRK2, has been resolved by crystallography and this 
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Recent molecular modelling studies of rat TASK-1 and rat TASK-3 channels using TASK 
selective inhibitory compounds such as A1899, PKTHPP, ML365 and doxapram, have 
suggested a common intracellular binding site, within the pore region of these channels.20-22 
To further elucidate the molecular mode of action of doxapram on human channels, we 
examined previously identified hydrophobic residues in rat, located on the M2 and M4 
transmembrane regions of TASK-3, that face the pore region of the channel. These residues 
are suggested to form a common intracellular binding site for a number of respiratory 
stimulants, including doxapram. In particular, mutation of a leucine (L) on the M2 region, 
L122, and another on the M4 region, L239, significantly attenuates doxapram effect. It has 
previously been suggested that L122 and L239, create a hydrophobic narrowing of the pore, 
which affects the potency of three breathing stimulants, PKTHPP, A1899, and doxapram.22 
When these normally hydrophobic residues are mutated to hydrophilic (lipid-repelling) 
residues, such as aspartate residues, this creates a barrier in the pore, due to either an 
increase of water and potassium ion occupancy in the pore and/or this region acts as a 
fulcrum point for channel gating, preventing access of the drug.22 This correlates with 
another previous molecular modelling study of doxapram, which suggests the drug has a 
high affinity for a hydrophobic cleft in which to bind40  and with a study conducted on TASK-
3_L122D, which suggested that mutating this amino acid to an aspartate produces a fixed 
open conformation that reduces the effects of anaesthetics.29 As well as for doxapram22 the 
L239 residue has previously been identified in TASK-1 for its involvement in A1899 
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In our experimental conditions, the currents recorded through all four mutant channels 
(L122D, G236D, L239D and V242D) are significantly larger than for WT channels, suggesting 
that the channel may be gated into an open confirmation, reducing the efficacy of 
inhibitors, such as doxapram, similar to that seen with the T3_Δ250 channel.  
 
For L122D in particular, the mutation that caused the most dramatic reduction in doxapram 
effect, it has recently been shown that D or N mutations at this position in all K2P channels 
act as gain of function mutations42 and mutations at this position alter the effectiveness of a 
number of K2P channel regulators.42,43 This may confound interpretation of functional 
experiments that suggest this residue is involved in regulator binding. To address this, we 
investigated whether this particular mutation attenuated the effect of another known TASK-
3 antagonist, zinc, which has been shown to act on residues on the extracellular side of the 
channel.30,31 This mutation had no effect on zinc inhibition of the channel, which is in 
agreement with the hypothesis that doxapram does indeed act at a site within the 
intracellular pore region of the channel.22  
 
Since the submission of this manuscript a crystal structure of TASK-1, bound to inhibitory 
compounds, was released.44 The resolved structure, revealed the presence of a unique gate, 
termed “X-gate”, at the intracellular entrance to the vestibule, formed from a 
conformational rearrangement of the M4 helices, involving the VLRFMT region. For two 
novel inhibitory compounds (BAY 1000493 and BAY 2341237) it was shown that the 
compounds bind within an inner vestibule, directly below the selectivity filter. Consistent 
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were important for binding and trapping of these inhibitory compounds, within TASK-1 
channels. In particular, they found that L122 projected into the vestibule below the 
compounds, holding them in place and this was thought to be responsible for the slow 
compound washout rates observed for these and others compounds.15 Indeed, we also 
observed that for TASK-1, washout of doxapram, was slow and often incomplete, however, 
this was not true for TASK-3. This suggests that despite high sequence similarity between 
TASK-1 and TASK-3 in this region, the arrangement of amino acids within the vestibule and 
the X-gate (VLRFMT for TASK-1, but VLRFLT for TASK-3) may differ slightly between the two 
channels and perhaps also for heterodimers of the channels.   
 
Interestingly, another putative doxapram binding residue, G236, is mutated to a large 
positively charged arginine (R) in a condition known as Birk Barel Mental Retardation 
Syndrome or more recently, KCNK9 Imprinting syndrome.23,45 In this homodimeric 
conformation the channel is poorly functioning, with low current levels, which are inwardly-
rectifying and show altered potassium selectivity.46 When G236 is mutated to an aspartate 
however, the current is significantly increased through these channels, remains outwardly 
rectifying and potassium selective.  
 
We have also shown that chiral separation of doxapram into its positive and negative 
enantiomers, results in a highly potent inhibitory eutomer (GAL-054), which was 2-fold more 
potent than doxapram and a poorly inhibitory distomer (GAL-053) when tested on human 
cloned channels, transiently expressed in a human tsA201 cells. These data correlate nicely 
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dose-dependently increased minute volume when administered intravenously, whilst GAL-
053, had no effect.24-26 It was also observed in these studies that some of the known side-
effects of this drug, were restricted to the distomer, raising hope for an improved 
ventilatory stimulant, with few side-effects. Disappointingly, the known pressor effects of 
doxapram in human and dogs47,48 were still evident with GAL-054. In conscious rats and in 
healthy human volunteers of a Phase 1 clinical trial. GAL-054 was found to increase blood 
pressure by 15-20% (unpublished data, Galleon Pharmaceuticals)27 and consequently was 
no longer pursued due to patient safety concerns. It has been suggested that this observed 
increase in blood pressure may occur due to an increase in catecholamine levels during 
administration of doxapram.49 As the proposed mechanism of action by which doxapram 
reverses respiratory depression is via the direct stimulation of peripheral chemoreceptors of 
type 1 cells within the carotid bodies, resulting in a subsequent release of 
catecholamines.4,50 It remains possible that any drugs that target TASK channels in carotid 
bodies, may also increase blood pressure. It should also be borne in mind that the 
hemodynamic reflex response to selective stimulation of carotid body chemoreceptors is 
complex and often described as context specific, and that evoked ventilatory stimulation 
can be associated with early pressor and later depressor effects.51,52,53 
In our study, all experiments were performed using human cell lines in normoxic conditions 
at room temperature. Whilst this gives consistency of basal responses on which to measure 
the effects of doxapram, it is also a limitation as we did not investigate the effects of 
doxapram under conditions of hypoxia, which causes an inhibition of both TASK-1 and TASK-
3 channels, or at normal body temperature. In clinical conditions, doxapram is often used in 
hypoxic conditions and always at body temperature, which makes it less easy for us to 
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Nevertheless, the data reported here showing that the effect on TASK channels is restricted 
to the positive enantiomer; the differential potencies between human and murine channels 
and the molecular information regarding a potential intracellular binding site within the 
pore region of TASK channels, will be of benefit for the design of new therapeutic molecules 
with higher potency, higher specificity and fewer associated side effects.  
 
Methods: 
Molecular Biology. Murine (mur) wild-type (WT) TASK-1 (KCNK3, GenbankTM DQ185133) 
and WT mur TASK-3 (KCNK9, GenbankTM AH009585.2) cDNA were cloned into pCS2+ vector 
and were a kind gift from William Wisden (Imperial College, UK). Human WT TASK-1 
(GenbankTM AF006823.1), WT TASK-3 (GenbankTM AF212829) and WT TASK-2 (KCNK5, 
GenbankTM AF084830.1) cDNA’s, were cloned into pcDNA3.1+ vector (Invitrogen, Carlsbad, 
CA, USA) and were a kind gift from Helen Meadows (GlaxoSmithKline, Harlow, UK).  
 
Mutations. Point mutations (L122D, G236D, L239D, V242D or a stop codon) were 
introduced by site-directed mutagenesis into TASK-3 cDNA using the Quikchange kit 
(Stratagene, La Jolla, CA, USA) as previously described.54  
 
Cell Culture. All experiments were performed using a modified human embryonic kidney 
293 cell line, tsA201 (ECACC; Sigma-Aldrich, Gillingham, Dorset, UK), prepared and 
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Transfection. For the electrophysiological experiments, cells were transiently transfected 
using a modified calcium-phosphate protocol, following a process as previously described.54 
Vectors cloned with the gene of interest and a similar vector encoding the cDNA for green 
fluorescent protein (GFP) were added to each well at a concentration of 0.5 µg per well, 
with the exception being for murTASK-3, where 0.125 µg per well was used.  
 
Whole-Cell Patch-Clamp Electrophysiology. Currents were recorded from tsA201 cells 
transiently transfected with the channel of interest using whole-cell patch-clamp in a 
voltage clamp configuration and a step-ramp voltage protocol as previously described.54 
Briefly, all experiments were conducted at room temperature (20 – 24 oC) using an external 
solution composed of 145 mM NaCl, 2.5 mM KCL, 3 mM MgCl2, 1 mM CaCl2 and 10 mM 
HEPES (pH 7.4, using NaOH) and an intracellular pipette solution composed of 150 mM KCL, 
3 mM MgCl2, 5 mM EGTA and 10 mM HEPES (pH adjusted to 7.4 with KOH). External 
solution and modulatory compounds were superfused at a rate of 4-5 mL min-1. Currents 
were recorded using an Axopatch 1D patch clamp amplifier (Molecular Devices, Sunnyvale, 
CA), filtered at 0.3 kHz, digitized at 1 kHz.  
 
Data Analysis and Statistics:  
For analysis of outward current, we measured the current difference between the -80 and -
40 mV. The current-voltage graphs were obtained from the ramp change in voltage between 
-120 and +20 mV. For each cell, the current amplitude (pA) was normalized to the cell 
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(Molecular Devices), Microsoft Excel (Redmond, WA) and GraphPad Prism 6 or 7 software 
(San Diego, CA). Data were expressed as the mean ± 95% Confidence Intervals (CI), and n 
represents the number of individual cells. For EC50 calculations, concentration-response 
curves were fitted using the Hill equation. Statistical analysis used were one-way ANOVA 
with a post-hoc Dunnett’s test or an unpaired/paired Student’s t-test. Data was considered 
statistically different if P < 0.05. The data and statistical analysis comply with the 
recommendations on experimental design and analysis in pharmacology.55 
 
Chemicals: Doxapram, GAL-053 and GAL-054 were a kind gift of Galleon Pharmaceuticals 
Inc., PA, USA and were prepared in water to create 10 mM stock solutions that were then 
diluted, in external solution, to desired concentration just before use. Zinc Chloride was 
purchased from Sigma-Aldrich and was made up in water to create a 100 mM stock. 
 
Homology Modelling: hTASK3 (UniProtKB/Swiss-Prot ID Q9NPC2) and mTASK3 
(UniProtKB/Swiss-Prot ID Q3LS21) homology models were developed as previously 
described45 using Modeller 9v8.56 The human TWIK-related arachidonic acid activated K 
(TRAAK) structure (PDB ID 3UM7)57 was used as a template for TASK3 modelling, ClustalW58 
was used to align the TRAAK and TASK3 sequences. 
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Legends to Figures: 
 
Figure 1: Effect of doxapram on human cloned TASK-1, TASK-3 and TASK-2 channels. [A] 
Concentration-response curve for doxapram inhibition of human (h) TASK-1 current. [B] 
hTASK-1 currents evoked by ramp changes in voltage in control conditions and in the 
presence of doxapram over a range of concentrations (0.3 – 100 µM). [C] Concentration-
response curve for doxapram inhibition of hTASK-3 current. [D] hTASK-3 currents evoked by 
ramp changes in voltage in control conditions and in the presence of doxapram over a range 
of concentrations (0.3 – 100 µM). [E] A plot of % inhibition by 10 µM doxapram from 
individual cells expressing either hTASK-1, hTASK-3 or hTASK-2 human cDNA. Error bars 
represent the 95% CI. *P<0.05, ****P<0.0001; One-way ANOVA, followed by a Dunnett’s 
multiple comparisons test. [F] Time course plot showing the acute application of 10 µM 
Doxapram (blue line) on hTASK-2 current. Each point is a 5 millisecond (ms) average of the 
difference current between that at -40 mV and that at -80 mV (see methods for detailed 
description of voltage-ramp protocol). 
 
Figure 2: Effect of doxapram on mouse cloned TASK-1, TASK-3 homodimeric and forced 
heterodimeric channels. [A] Concentration-response curve for doxapram inhibition of 
murTASK-1 current over a range of concentrations (0.3 – 100 µM). [B] Concentration-
response curve for doxapram inhibition of murTASK-3 current over a range of 
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cells expressing either homodimeric murTASK-3 (T3), homodimeric murT1, heterodimeric 
murT3_murT1, and heterodimeric murT1_murT3 cDNA. Error bars represent the 95%. [D] 
raw data trace from exemplar mouse heterodimeric murT1_murT3 in control (black line) 
and 10 µM doxapram (blue line) using a step-ramp voltage protocol as detailed in the 
Methods. 
 
Figure 3: Removal of the carboxy terminal of murTASK-3 attenuates doxapram effect 
further. [A] Cartoon to depict the amino acid structure of the carboxy terminal of murTASK-
3, the location of putative phosphorylation sites and the introduction of the stop codon. [B] 
Box and Whiskers plot of doxapram (10 µM) inhibition of murT3_Δ250 and murT3 wild type. 
Bars represent the min and max inhibition for each channel type. [C] murT3_ Δ250 currents 
evoked by ramp changes in voltage from -120 to +20 mV in control conditions (black line) 
and in the presence of 10 µM doxapram (blue line). 
 
Figure 4: Removal of the carboxy terminal of human TASK-3 attenuates doxapram effect. 
[A] Cartoon to compare the identity of the amino acid structure of the carboxy terminal of 
human TASK-3 and human TASK-1. [B] Box and Whiskers plot of doxapram (10 µM) 
inhibition of human (h) T3_Δ250 and WT hT3. Bars represent the min and max inhibition for 
each channel type. [C] hT3_ Δ250 currents evoked by ramp changes in voltage from -120 to 
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Figure 5: Computer homology model of human TASK-3 channel with indicated putative 
binding site. [A] Homology model of human TASK-3 channel based upon TRAAK crystal 
structure (PDB ID 3UM7)54 depicting location of the four amino acids (AA) that form the 
putative site, L122, G236, L239, and V242 (shown with arrows) as viewed from beneath the 
channel. [B] AA sequence alignment of human TASK-1 and TASK-3. Dashes represent gaps in 
the sequence and numbers represent the position of the starting AA. The black box 
highlights the AA’s that form the putative site. 
 
Figure 6: Pore-lining residues of the M2 and M4 domains are influenential for doxapram 
inhibition of the human TASK-3 channel. [A] graph of current density (pA pF-1) measured 
from individual cells transiently expressing WT TASK-3, TASK-3_L122D, TASK-3_G236D, 
TASK-3_L239D, TASK-3_V242D and GFP-only. Error bars represent the 95% CI and * 
statistical significance [*P<0.05; ****P<0.0001]. [B] A plot of zero current level (mV) 
measured from individual cells transiently expressing WT TASK-3, TASK-3_L122D, TASK-
3_G236D, TASK-3_L239D, TASK-3_V242D and GFP-only. Error bars represent the 95% CI. [C] 
Box and Whiskers plot of doxapram (10 µM) inhibition of WT TASK-3, TASK-3_L122D, TASK-
3_G236D, TASK-3_L239D and TASK-3_V242D. Bars represent the min and max inhibition for 
each channel type. [D] hT3_ L122D currents evoked by ramp changes in voltage from -120 to 
+20 mV in control conditions (black line) and in the presence of 10 µM doxapram (blue line). 
[E] Box and Whiskers plot of zinc (100 µM) inhibition of WT TASK-3 and TASK-3_L122D. Bars 
represent the min and max inhibition for each channel type. [F] hT3_ L122D currents evoked 
by ramp changes in voltage from -120 to +20 mV in control conditions (black line) and in the 
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Figure 7: The (+) – enantiomer (GAL-054) is responsible for the inhibitory effects observed 
with doxapram on human TASK channels. [A] A plot of % inhibition of 1, 3 and 10 µM GAL-
054 on human TASK-1 channels. Each point represents an individual cell and the error bars 
represent the 95% CI. [B] human TASK-1 currents evoked by ramp changes in voltage from -
120 to +20 mV in control conditions (black line) and in the presence of 10 µM GAL-054 (red 
line). [C] A plot of % inhibition of 1, 3 and 10 µM GAL-054 on human TASK-3 channels. [D] 
human TASK-3 currents in control conditions (black line) and in the presence of 10 µM GAL-
054 (red line). [E] A plot of % inhibition of 10, 100 and 300 µM GAL-053 on human TASK-1 
channels. [F] human TASK-1 currents in control conditions (black line) and in the presence of 
10 µM GAL-053 (green line). [G] A plot of % inhibition of 10, 100 and 300 µM GAL-053 on 
human TASK-3 channels. [H] human TASK-3 currents in control conditions (black line) and in 
the presence of 10 µM GAL-053 (green line). The specificity observed with mouse TASK 
channels remained unchanged with for the (+) – enantiomer GAL-054, with the enantiomer 
being twice as potent on murTASK-1 channels compared with murTASK-3 (data not shown). 
A concentration of 10 µM inhibited murTASK-1 channels by 63% [95% CI = 61 to 65, n=3] 
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